18 December 2018
Visiongain has launched a new pharma report Global Bioreactors Market 2019-2029: 5L-20L, 20L-200L, 200L-1500L, Above 1500L, Single-Use, Glass, Stainless Steel, Lab-Scale, Pilot-Scale, Full-Scale, R&D Departments, Biopharmaceutical Manufacturers, Contract Research Organizations, Other End-Users.
The biopharmaceutical contract manufacturing market has significantly expanded over the past years. The rising interest of pharmaceutical organizations to enter the biopharmaceutical market will result in consolidation in the form of strategic alliances between contract manufacturing organizations (CMO’s) and large pharmaceutical/biotechnology organizations. This will result in increased investments and access to cutting-edge manufacturing technologies for CMOs.
Factors driving the bioreactors market growth include massive use of hybrid technologies, rise in the rate of adoption of single-use technologies, increasing popularity of single-use bioreactor among biopharmaceutical organizations, and a significant growth in the biologics market. However, regulatory challenges pertaining to single-use bioreactors and issues concerning leachable and extractable linked to single-use bags are some of the factors hampering the growth of bioreactors market.
The lead analyst of the report commented "There has been an unprecedented growth in the biologics and biosimilars market over the past years and these markets are likely to grow at double digit growth rate in the future years.
Therefore, owing to the expectations for robust growth in the biologic drugs demand, large number of manufacturers, including branded and biosimilar drug producers, are increasingly investing in the setting-up of new production facilities."
Leading companies featured in the report include Applikon Biotechnology Inc. (U.S.), BBI-Biotech GmbH (Germany), Bioengineering AG (Switzerland), Danaher Corporation (U.S), Eppendorf AG (Germany), GE Healthcare (A subsidiary of General Electric Company) (U.S.), Merck KGaA (Germany), Sartorius AG (Germany), Solaris Biotech (Italy), Thermo Fisher Scientific, Inc. (U.S.)
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The bioreactors market is expected to grow over the forecast period owing to the increase in adoption of single use technologies and the growing popularity among pharmaceutical companies regarding the potential benefits of single-use bioreactors.
25 March 2019
Growth will be restrained in the biosimilar growth hormones submarket by steady uptake for branded therapies, high brand loyalty, as well as the launch of long-acting growth hormones.
21 March 2019
ecent studies and expert opinion suggest that the asthma and COPD market is more segregated than previously believed.
19 March 2019
The intravenous route is the most commonly used route of administration owing to its high effectiveness during critical surgeries, its high adoption in hospitals, and availability of advanced intravenous drugs which cater the need of surgeons.